BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 22337825)

  • 1. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence.
    Kindy MS; Yu J; Zhu H; El-Amouri SS; Hook V; Hook GR
    J Alzheimers Dis; 2012; 29(4):827-40. PubMed ID: 22337825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
    Hook G; Yu J; Toneff T; Kindy M; Hook V
    J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
    Hook G; Hook V; Kindy M
    J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid-β in hAβPP Mouse Models Representing the Major Sporadic Alzheimer's Disease Condition.
    Hook G; Kindy M; Hook V
    J Alzheimers Dis; 2023; 93(1):33-46. PubMed ID: 36970896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.
    Kimura R; Devi L; Ohno M
    J Neurochem; 2010 Apr; 113(1):248-61. PubMed ID: 20089133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein.
    Hook VY; Kindy M; Hook G
    J Biol Chem; 2008 Mar; 283(12):7745-53. PubMed ID: 18184658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.
    Hook V; Hook G; Kindy M
    Biol Chem; 2010 Aug; 391(8):861-72. PubMed ID: 20536395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease.
    Oulès B; Del Prete D; Greco B; Zhang X; Lauritzen I; Sevalle J; Moreno S; Paterlini-Bréchot P; Trebak M; Checler F; Benfenati F; Chami M
    J Neurosci; 2012 Aug; 32(34):11820-34. PubMed ID: 22915123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice.
    Devi L; Ohno M
    Eur J Neurosci; 2010 Jan; 31(1):110-8. PubMed ID: 20092558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
    Devi L; Ohno M
    Neuroscience; 2015 Oct; 307():128-37. PubMed ID: 26314636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease.
    Li L; Zhang S; Zhang X; Li T; Tang Y; Liu H; Yang W; Le W
    Curr Alzheimer Res; 2013 May; 10(4):433-41. PubMed ID: 23305067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases.
    Cai Z; Wang C; He W; Chen Y
    Curr Alzheimer Res; 2018; 15(11):1045-1052. PubMed ID: 29962345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor.
    Shin KY; Noh SJ; Park CH; Jeong YH; Chang KA; Yoo J; Kim HJ; Ha S; Kim HS; Park HJ; Lee JH; Moon C; Suh YH
    CNS Neurol Disord Drug Targets; 2016; 15(8):935-944. PubMed ID: 27577574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic deficits are rescued in the p25/Cdk5 model of neurodegeneration by the reduction of β-secretase (BACE1).
    Giusti-Rodríguez P; Gao J; Gräff J; Rei D; Soda T; Tsai LH
    J Neurosci; 2011 Nov; 31(44):15751-6. PubMed ID: 22049418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease.
    Havas D; Hutter-Paier B; Ubhi K; Rockenstein E; Crailsheim K; Masliah E; Windisch M
    J Alzheimers Dis; 2011; 25(2):231-43. PubMed ID: 21403389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-O-methylhonokiol prevents memory impairment in the Tg2576 transgenic mice model of Alzheimer's disease via regulation of β-secretase activity.
    Lee YJ; Choi DY; Lee YK; Lee YM; Han SB; Kim YH; Kim KH; Nam SY; Lee BJ; Kang JK; Yun YW; Oh KW; Hong JT
    J Alzheimers Dis; 2012; 29(3):677-90. PubMed ID: 22330831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
    Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
    J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.
    Caccamo A; Branca C; Talboom JS; Shaw DM; Turner D; Ma L; Messina A; Huang Z; Wu J; Oddo S
    J Neurosci; 2015 Oct; 35(41):14042-56. PubMed ID: 26468204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease.
    Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM
    BMC Neurosci; 2019 Mar; 20(1):13. PubMed ID: 30894120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.